3.465

4.53% 0.155

Scpharmaceuticals Inc (SCPH)

Overview News Price History Option Chain Financials Discussions Forecast

Scpharmaceuticals Inc stock is traded at $3.465, with a volume of 178.70K. It is up +4.53% in the last 24 hours and up +37.85% over the past month. scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.

Previous Close:

$3.31

Open:

$3.4

24h Volume:

178.70K

Relative Volume:

0.38

Market Cap:

$182.69M

Revenue:

$17.63M

Net Income/Loss:

$-57.71M

P/E Ratio:

-2.3412

EPS:

-1.48

Net Cash Flow:

$-60.45M

1W Performance:

+5.17%

1M Performance:

+37.85%

6M Performance:

-7.49%

1Y Performance:

-1.42%

1-Day Range:

$3.23

$3.51

1-Week Range:

$3.2018

$3.5688

52-Week Range:

$1.94

$5.65

Scpharmaceuticals Inc Stock (SCPH) Company Profile

Name

Scpharmaceuticals Inc

Sector

Healthcare (1173)

Industry

Biotechnology (666)

Phone

617-517-0730

Address

25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA

Employee

Twitter

@scPharmaUSA

Next Earnings Date

2025-03-19

Latest SEC Filings

SCPH's Discussions on Twitter

Compare SCPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCPH Scpharmaceuticals Inc	3.4607	185.83M	17.63M	-57.71M	-60.45M	-1.48
ONC Beigene Ltd Adr	238.92	25.23B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	444.79	113.16B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.26	40.65M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	605.13	64.41B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	75.06	6.18B	0	-153.72M	-103.81M	-2.00

Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-07-23	Initiated	Craig Hallum	Buy
Dec-01-22	Initiated	Cowen	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Oct-11-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Aug-02-22	Initiated	Maxim Group	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Oct-15-19	Initiated	H.C. Wainwright	Buy
Jan-30-19	Downgrade	Leerink Partners	Outperform → Mkt Perform

View All

Scpharmaceuticals Inc Stock (SCPH) Latest News

May 23, 2025

Captrust Financial Advisors Acquires 21,523 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World

May 23, 2025

May 22, 2025

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025 - Seeking Alpha

May 22, 2025

May 19, 2025

Price T Rowe Associates Inc. MD Buys Shares of 15,143 scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World

May 19, 2025

scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Purchased by Comerica Bank - Defense World

May 19, 2025

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript - Insider Monkey

May 16, 2025

Market Sentiment Around Loss-Making scPharmaceuticals Inc. (NASDAQ:SCPH) - simplywall.st

May 16, 2025

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

May 16, 2025

May 15, 2025

scPharmaceuticals Earnings Call Highlights Growth and Expansion - TipRanks

May 15, 2025

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory - MSN

May 15, 2025